These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

188 related articles for article (PubMed ID: 9624537)

  • 1. Molecular cytogenetic delineation of the critical deleted region in the 5q- syndrome.
    Jaju RJ; Boultwood J; Oliver FJ; Kostrzewa M; Fidler C; Parker N; McPherson JD; Morris SW; Müller U; Wainscoat JS; Kearney L
    Genes Chromosomes Cancer; 1998 Jul; 22(3):251-6. PubMed ID: 9624537
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cytogenetic features of 5q deletion and 5q- syndrome in myelodysplastic syndrome in Korea; marker chromosomes proved to be chromosome 5 with interstitial deletion by fluorescence in situ hybridization.
    Lee HR; Oh B; Hong DS; Zang DY; Yoon HJ; Kim HJ; Kim I; Ahn JS; Cheong JW; Lee KA; Cho KS; Lee MH; Bang SM; Kim TY; Yun YM; Min YH; Lee YK; Lee DS;
    Cancer Genet Cytogenet; 2010 Dec; 203(2):193-202. PubMed ID: 21156233
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Deletion of 5q31 is observed in megakaryocytic cells in patients with myelodysplastic syndromes and a del(5q), including the 5q- syndrome.
    Godon C; Talmant P; Garand R; Accart F; Bataille R; Avet-Loiseau H
    Genes Chromosomes Cancer; 2000 Dec; 29(4):350-2. PubMed ID: 11066080
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A cryptic deletion in 5q31.2 provides further evidence for a minimally deleted region in myelodysplastic syndromes.
    MacKinnon RN; Kannourakis G; Wall M; Campbell LJ
    Cancer Genet; 2011 Apr; 204(4):187-94. PubMed ID: 21536236
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A new recurrent translocation, t(5;11)(q35;p15.5), associated with del(5q) in childhood acute myeloid leukemia. The UK Cancer Cytogenetics Group (UKCCG).
    Jaju RJ; Haas OA; Neat M; Harbott J; Saha V; Boultwood J; Brown JM; Pirc-Danoewinata H; Krings BW; Müller U; Morris SW; Wainscoat JS; Kearney L
    Blood; 1999 Jul; 94(2):773-80. PubMed ID: 10397745
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cytogenetic and molecular delineation of the smallest commonly deleted region of chromosome 5 in malignant myeloid diseases.
    Le Beau MM; Espinosa R; Neuman WL; Stock W; Roulston D; Larson RA; Keinanen M; Westbrook CA
    Proc Natl Acad Sci U S A; 1993 Jun; 90(12):5484-8. PubMed ID: 8516290
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Fluorescence in situ hybridization improves the detection of 5q31 deletion in myelodysplastic syndromes without cytogenetic evidence of 5q-.
    Mallo M; Arenillas L; Espinet B; Salido M; Hernández JM; Lumbreras E; del Rey M; Arranz E; Ramiro S; Font P; González O; Renedo M; Cervera J; Such E; Sanz GF; Luño E; Sanzo C; González M; Calasanz MJ; Mayans J; García-Ballesteros C; Amigo V; Collado R; Oliver I; Carbonell F; Bureo E; Insunza A; Yañez L; Muruzabal MJ; Gómez-Beltrán E; Andreu R; León P; Gómez V; Sanz A; Casasola N; Moreno E; Alegre A; Martín ML; Pedro C; Serrano S; Florensa L; Solé F
    Haematologica; 2008 Jul; 93(7):1001-8. PubMed ID: 18591625
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Incidence of 17p deletions and TP53 mutation in myelodysplastic syndrome and acute myeloid leukemia with 5q deletion.
    Sebaa A; Ades L; Baran-Marzack F; Mozziconacci MJ; Penther D; Dobbelstein S; Stamatoullas A; Récher C; Prebet T; Moulessehoul S; Fenaux P; Eclache V
    Genes Chromosomes Cancer; 2012 Dec; 51(12):1086-92. PubMed ID: 22933333
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Fluorescence in situ hybridization for del(5q) in myelodysplasia/acute myeloid leukemia: comparison of EGR1 vs. CSF1R probes and diagnostic yield over metaphase cytogenetics alone.
    Sun Y; Cook JR
    Leuk Res; 2010 Mar; 34(3):340-3. PubMed ID: 19608274
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Lenalidomide inhibits the malignant clone and up-regulates the SPARC gene mapping to the commonly deleted region in 5q- syndrome patients.
    Pellagatti A; Jädersten M; Forsblom AM; Cattan H; Christensson B; Emanuelsson EK; Merup M; Nilsson L; Samuelsson J; Sander B; Wainscoat JS; Boultwood J; Hellström-Lindberg E
    Proc Natl Acad Sci U S A; 2007 Jul; 104(27):11406-11. PubMed ID: 17576924
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A prognostic impact of separation of refractory cytopenia with multilineage dysplasia and 5q- syndrome from refractory anemia in primary myelodysplastic syndrome.
    Cermák J; Michalová K; Brezinová J; Zemanová Z
    Leuk Res; 2003 Mar; 27(3):221-9. PubMed ID: 12537974
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Loss of both CSF1R (FMS) alleles in patients with myelodysplasia and a chromosome 5 deletion.
    Boultwood J; Rack K; Kelly S; Madden J; Sakaguchi AY; Wang LM; Oscier DG; Buckle VJ; Wainscoat JS
    Proc Natl Acad Sci U S A; 1991 Jul; 88(14):6176-80. PubMed ID: 1829836
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Delineation by molecular cytogenetics of 5q deletion breakpoints in myelodyplastic syndromes and acute myeloid leukemia.
    Royer-Pokora B; Trost D; Müller N; Hildebrandt B; Germing U; Beier M
    Cancer Genet Cytogenet; 2006 May; 167(1):66-9. PubMed ID: 16682289
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Deletions of chromosome 5 in malignant myeloid disorders.
    Le Beau MM
    Cancer Surv; 1992; 15():143-59. PubMed ID: 1451109
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Combined immunophenotyping and FISH identifies the involvement of B-cells in 5q- syndrome.
    Jaju RJ; Jones M; Boultwood J; Kelly S; Mason DY; Wainscoat JS; Kearney L
    Genes Chromosomes Cancer; 2000 Nov; 29(3):276-80. PubMed ID: 10992302
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Myelodysplastic syndromes with del(5q): indications and strategies for cytogenetic testing.
    Haferlach C; Bacher U; Tiu R; Maciejewski JP; List A
    Cancer Genet Cytogenet; 2008 Dec; 187(2):101-11. PubMed ID: 19027491
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Polymerase chain reaction-based diagnosis of del (5q) in acute myeloid leukemia and myelodysplastic syndrome identifies a minimal deletion interval.
    Horrigan SK; Westbrook CA; Kim AH; Banerjee M; Stock W; Larson RA
    Blood; 1996 Oct; 88(7):2665-70. PubMed ID: 8839861
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Interphase FISH does not improve the detection of DEL(5q) and DEL(20q) in myelodysplastic syndromes.
    Douet-Guilbert N; Herry A; LE Bris MJ; Guéganic N; Bovo C; Morel F; DE Braekeleer M
    Anticancer Res; 2011 Mar; 31(3):1007-10. PubMed ID: 21498729
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Chromosome 5q deletion and epigenetic suppression of the gene encoding alpha-catenin (CTNNA1) in myeloid cell transformation.
    Liu TX; Becker MW; Jelinek J; Wu WS; Deng M; Mikhalkevich N; Hsu K; Bloomfield CD; Stone RM; DeAngelo DJ; Galinsky IA; Issa JP; Clarke MF; Look AT
    Nat Med; 2007 Jan; 13(1):78-83. PubMed ID: 17159988
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Novel genes mapping to the critical region of the 5q- syndrome.
    Boultwood J; Fidler C; Soularue P; Strickson AJ; Kostrzewa M; Jaju RJ; Cotter FE; Fairweather N; Monaco AP; Müller U; Lovett M; Jabs EW; Auffray C; Wainscoat JS
    Genomics; 1997 Oct; 45(1):88-96. PubMed ID: 9339364
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.